Business Context and Reporting Period
This November 25, 2019 Form 8-K, reporting events occurring November 19–22, 2019, was filed by Amplitude Healthcare Acquisition Corporation, not Jasper Therapeutics, Inc. The registrant was a special purpose acquisition company (SPAC) completing its initial public offering (IPO).
Key Financial Metrics and Capitalization
| Item | Amount or Terms |
|---|---|
| IPO units issued | 10,000,000 units |
| IPO price and gross proceeds | $10.00 per unit; $100.0 million gross proceeds |
| Underwriter over-allotment option | Up to 1,500,000 additional units |
| Private placement warrants | 4,000,000 warrants sold to the sponsor at $1.00 each; $4.0 million gross proceeds |
| Public warrant terms | Each whole warrant is exercisable for one Class A common share at $11.50 per share |
| Trust account funding | $100.0 million deposited, consisting of $98.0 million of IPO proceeds and $2.0 million of private placement proceeds |
| Financial performance | The filing does not provide revenue, net income, cash flow, margins, debt, or other operating-period financial results. |
Material Changes and Transaction Details
- The IPO closed on November 22, 2019, following pricing on November 19, 2019.
- The company entered into underwriting, warrant, trust, sponsor, registration rights, and related agreements.
- The sponsor’s private placement warrants are generally restricted from transfer until 30 days after the initial business combination and are not redeemable for cash while held by the sponsor or permitted transferees.
- An amended and restated certificate of incorporation became effective on November 19, 2019.
Outlook, Risks, Contingencies, and Unusual Items
- The company’s principal objective was to complete an initial business combination; the filing does not identify a target or provide operating guidance.
- Trust-account funds generally cannot be released until the initial business combination, an approved redemption-related amendment, or redemption of public shares if no business combination is completed within 24 months of the IPO closing.
- If no qualifying business combination is completed within that 24-month period, public shares are subject to redemption, subject to applicable law.
- Interest earned in the trust account may be released to pay taxes.
- The IPO and private placement create potential dilution through public and sponsor warrants and the underwriters’ over-allotment option.
Important Facts for Investors to Verify
- Confirm the filing issuer: the submitted text concerns Amplitude Healthcare Acquisition Corporation, not Jasper Therapeutics, Inc.
- Review the definitive warrant agreement for exercise, redemption, and adjustment provisions.
- Verify the final number of units issued after any exercise of the over-allotment option.
- Review the trust agreement and amended charter for redemption rights and the 24-month business-combination deadline.
- Assess dilution from the 4.0 million private placement warrants, public warrants, and any sponsor securities.